BIOMAT Database Logo BIOMAT Database Logo

[Effect of levamisole hydrochloride on advanced and recurrent breast cancer--LMS randomized controlled study of a group responding to CAF (cyclophosphamide, adriamycin, and 5-FU) therapy]. 1982

T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura

The effect of levamisole HCL on advanced and recurrent breast cancer was investigated cooperatively by a randomized controlled study using envelope method. Patients with advanced and recurrent breast cancer who had showed either complete response or partial response to the previous CAF therapy (cyclophosphamide 100 mg/body/day p.o. from day 1 to 14, adriamycin 30 mg/body/day i.v. on day 1 and 8, 5-FU 500 mg/body/day i.v. on day 1 and 8) were entered in this study and divided randomly into a control group and a levamisole group. No further treatment was given to patients of the control group until they fell into progressive disease. Patients of the levamisole group were given the drug at a daily dose of 150 mg for 3 consecutive days every fortnight. Fifty-nine cases were entered in this protocol, but 9 cases of them were ruled out as exclusions or dropouts. Therefore, the number of eligible cases was 31 in the levamisole group and 19 in the control group. Both the duration of remission and the survival time were significantly (p less than 0.05) prolonged in the levamisole group compared with the control group. There was no difference in side effects between these two groups.

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
May 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].
September 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
December 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer.
January 1999, Breast cancer (Tokyo, Japan),
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
December 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
March 1980, The Medical journal of Australia,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
January 1991, Neoplasma,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
January 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
January 1983, Breast cancer research and treatment,
T Taguchi, and M Izuo, and N Ogawa, and H Hayasaka, and S Akai, and S Tazima, and G Fujii, and T Tominaga, and T Okamoto, and K Kubo, and M Yoshida, and K Ota, and K Sakai, and T Hattori, and G Inoue, and Y Nomura
[Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials].
January 1989, Bulletin du cancer,
Copied contents to your clipboard!